Dr. LeBel has more than 20 years of pharmaceutical research and development (R&D) experience including significant leadership expertise in critical areas such as product development, preclinical and clinical research and regulatory strategy. His career has spanned multiple life science companies, including a 14-year tenure with Amgen that was marked by multiple product successes and key clinical trial innovations. While at Amgen, he guided the successful execution of the registration programs for both Prolia® and Xgeva®, while overseeing a large project management staff that supported the company’s entire portfolio of oncology supportive care therapeutics (Aranesp®, Neulasta®/Neupogen®, Kepivance®, and Nplate®). In addition, Dr. LeBel is credited with the design and deployment of an innovative data capture platform that supported Amgen’s efforts in global clinical trial tracking and management.
Since joining Otonomy, Dr. LeBel has spearheaded the company’s R&D activities including the advancement of the OTO-104 and OTO-201 development programs. As part of this work, he has built a world-class R&D team with vast expertise in the development of preclinical ear disease models, as well as conducting human clinical trials for both inner and middle ear disorders.
Dr. LeBel holds a BS in Chemistry from the University of Detroit, a PhD in Biomedical Sciences/Toxicology from Northeastern University, and was a NIEHS postdoctoral fellow in Community and Environmental Medicine at the University of California, Irvine. He is also a Scientific Fellow of the American Academy of Otolaryngology – Head & Neck Surgery, and a full member of both the American Association for the Advancement of Science and the Society of Toxicology.